Micronutrient Supplement for Nurse Burnout
Status unconfirmed · Not applicable · Has a placebo group
Conditions studied: Burnout, Professional, Stress, Psychological
In brief
The purpose of this study is to confirm and quantify the ability of an 8-week intervention with a supplement containing magnesium citrate and vitamin B6 to reduce anxiety, stress, and burnout among nurses working full time in hospitals and urgent care centers during the COVID-19 Pandemic.
Key facts
- Study ID
- NCT05363410
- Run by
- Nutraceuticals Research Institute
- People needed
- 88
- Starts
- 2022-05-01
- Expected to finish
- 2023-04-30
- Last updated by the study team
- 2022-05-05
Who can join
Age: 20 and older, up to 59. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Woman aged 20-59
- Lives in the United States
- In good general health as evidenced by medical history
- Stress subscale score from the DASS > =22
- Ability to take oral medication and be willing to commit to taking 3 tablets a day for 8 weeks.
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional month after the end of MagnéVie B6® administration
- Employed full time as a nurse in a hospital, primary, or urgent care center that treats COVID-19 patients. Full time is defined as 35 hours or more each week.
- Agreement to adhere to Lifestyle Considerations throughout study duration
You may not qualify if…
- Current use of the following pharmaceuticals: bisphosphonates, calcium channel blockers, digoxin, aminoglycoside antibiotics, ketamine, levodopa/carbidopa, gabapentin, potassium sparing diuretics, quinolone antibiotics, skeletal muscle relaxants, sulfonylureas, tetracycline antibiotics, amiodarone, antihypertensives, or antiepileptic drugs (including phenytoin, valproic acid, carbamazepine, phenobarbital).
- Pregnancy, trying to conceive or breastfeeding
- Known allergic reactions to any components of the supplement including magnesium citrate anhydrous, pyridoxine hydrochloride, lactose anhydrous, magnesium stearate, hypromellose, macrogol 6000 titanium dioxide, or talc
- Positive COVID-19 test within 60 days of the study period
- COVID vaccine of any type scheduled during the intervention period or the week prior to the start of the study
- Current diagnosis or lifetime history of a bleeding disorder, kidney disease, or neuromuscular disease
- Recent dramatic weight changes (10% change in body weight in the last 6 months)
- Existing usage of a magnesium or vitamin B6 supplement
Where it is running
- Franklin Health Research Center — Franklin, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.